RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:History Repeatswell, one complete response can be a fluke, two... and well, now things start to get interesting. From the latest data.
Furthermore, we've seen another complete response in an indication where checkpoint inhibitor therapy alone has had limited success historically, which bodes well for the potential of pelareorep to work synergistically with multiple immunotherapies in multiple tumor types."
The timelines still suck however. and they will either need to dilute/finance or partner to get this going... Kirk Look told us that the PanCan trial would reduce Phase III costs from 80 million to around 30 million. Presumably US dollars.
On top of that Panc Phase III is planned to start BEFORE mBC Phase III. When ONCY says middle of 2024 and doesn't state H1, then they mean September. Thus they will not have go/no go data unti H2 2025. Which would be a meaningful inflection point on the data. i.e. having statistically relevant data on efficacy... which is what we've all been waiting for.
Maybe with a second CR, Roche will be that elusive partner. There are faster horses out there methinks.